Connect global scientists and real-world data: Scientist contributes models + User distributed verification + Web3 value distribution
Scientists cannot access continuous, cross-lifecycle real-world health data
Scientists cannot access continuous, cross-lifecycle real-world health data
90% of biological models are only verified in laboratories, never tested with real patient populations
Pharmaceutical companies spend $26 billion annually on R&D but lack validated predictive models
Much research is buried in PDF papers and cannot be converted into productivity
Bio-GitHub: Scientists upload Python/R/ONNX model code
Distributed verification: Using users' local devices to run models, protecting privacy while verifying accuracy
NFT rights confirmation: Verified models are minted as NFTs, value dynamically increases with accuracy
Closed-loop trading: Pharmaceutical companies pay to call high-accuracy models, profits automatically distributed to contributors
Scientists build, users verify, pharmaceutical companies pay - a self-sustaining ecosystem
Model Builders
Data Contributors
Model Buyers
6-step positive cycle, model value grows exponentially with network scale
Users upload vital signs and symptom data (RWD)
Scientists upload algorithms and mint NFTs
Models run verification on user devices
Performance scores are tamper-proof
Tokens automatically distributed to contributors
More accurate models → More users
Diversified revenue structure, $180 million revenue explosion point in Year 3
Scientists sell model usage rights to B2B or B2C
Enterprise-level model licensing for clinical trials
Transaction fees, Gas fees and staking income
| Active Scientists | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Active Scientists | 100 | 500 | 2,000 | 8,000 | 20,000 |
| Deployed Models | 50 | 300 | 1,500 | 6,000 | 20,000 |
| Market Transaction Volume (GMV) | $100K | $800K | $5 million | $20 million | $60 million |
| Total Revenue | $50K | $400K | $2.5 million | $8 million | $20 million |
| Net Profit Margin | -120% | -60% | -10% | +15% | +25% |
Four advantages building the moat
Once the flywheel of scientist supply ↔ user data demand starts, it's extremely difficult to replicate
WellAlly's accumulated continuous real-world data (RWD) is unavailable in laboratories
The first blockchain-based scientific IP protection system, establishing a trust barrier
Edge computing architecture where data stays local, naturally compliant with HIPAA/GDPR
